RiaSTAP available for acute bleeding episodes

The FDA has approved RiaSTAP(purified fibrinogen concentrate, from CSL Behring) for the treatment of acutebleeding episodes in patients with congenital fibrinogen deficiency, includingafibrinogenemia and hypofibrinogenemia. 

The approval is based on a phaseII, open-label study which showed median fibrinogen plasma antigen levels andmedian fibrinogen plasma activity levels reached a maximum within 30 minutes(antigen) to 1 hour (activity) post-infusion and decreased continuouslyafterward. Study results also demonstrated a highly significant (p<0.0001)mean improvement in maximum clot firmness (MCF) from baseline to 1 hourpost-infusion following RiaSTAP treatment. 

For more information call (800)504-5434 or visit www.RiaSTAP.com.